Overactive Bladder Treatment Market Giants: Strategies, Financial Performance, and Future Outlook
The global overactive bladder treatment market is projected to reach USD 4.2 Billion by 2027 from USD 3.5 Billion in 2022, at a CAGR of 3.6% during the forecast period Major factors driving the market growth are rising prevalence of overactive bladder syndrome across the globe. Furthermore, launch of novel drugs with lesser side-effects coupled with adoption of technologically advanced treatment options for OAB treatment are also expected to support market growth in the coming years. Overactive bladder treatment market is fragmented and competitive in nature, several market players are adopting strategies to sustain market competition. The company offerings range from, various drugs, devices and botox that have larger geographic reach along with high product flexibility. Prominent players in the global overactive bladder treatment market are Astellas Pharma (Japan), Teva Pharmaceutical Industries (Israel), Pfizer (US), Medtronic (Ireland), AbbVie (US), Viatris (US), Hisa...